- Home
- PAXS vs MGTX Comparison
PAXS vs MGTX Comparison
Compare PAXS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAXS | MGTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.4M | 610.1M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PAXS | MGTX |
|---|---|---|
| Price | $15.57 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.83 |
| AVG Volume (30 Days) | 162.4K | ★ 282.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,279,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $569.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 137.42 |
| 52 Week Low | $13.63 | $4.73 |
| 52 Week High | $16.56 | $9.73 |
Technical Indicators
Market Signals| Indicator | PAXS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 50.41 |
| Support Level | $15.35 | $7.23 |
| Resistance Level | $15.64 | $8.15 |
| Average True Range (ATR) | 0.22 | 0.32 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 37.68 | 59.27 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.